Published in Diabetes Care on February 22, 2012
The treatment of type 2 diabetes. Dtsch Arztebl Int (2014) 2.66
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes (2013) 1.02
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care (2012) 0.95
How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. Diabetes Care (2013) 0.84
Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud (2015) 0.82
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.81
Effects of exenatide in a morbidly obese patient with type 2 diabetes. Diabetes Ther (2014) 0.78
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. Ther Clin Risk Manag (2015) 0.77
Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig (2012) 0.77
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS One (2016) 0.77
Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. Clin Epidemiol (2017) 0.76
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinol Metab (Seoul) (2016) 0.76
Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities. Am Health Drug Benefits (2015) 0.76
Emerging utility of once-weekly exenatide in patients with type 2 diabetes. Diabetes Metab Syndr Obes (2015) 0.76
A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol (2017) 0.75
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes (2017) 0.75
Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care. Diabetes Ther (2017) 0.75
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA (2000) 13.68
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care (2003) 7.80
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet (2010) 4.89
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia (2009) 2.98
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003) 1.66
Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care (2007) 1.50
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet (2010) 4.89
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature (2012) 3.41
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84
Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care (2009) 2.84
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J (2007) 2.56
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
The prevalence, anatomical correlates and treatment of sleep-disordered breathing in obese children and adolescents. Sleep Med Rev (2008) 2.33
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin (2008) 2.24
Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring. Diabetes Care (2006) 2.18
The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care (2002) 2.16
Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism (2006) 2.14
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care (2007) 2.14
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 2.12
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2005) 2.04
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Variants in the FTO gene are associated with common obesity in the Belgian population. Mol Genet Metab (2007) 1.82
Sleep-disordered breathing in overweight and obese children and adolescents: prevalence, characteristics and the role of fat distribution. Arch Dis Child (2006) 1.67
The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes (2007) 1.65
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther (2011) 1.57
Prevalence of loss-of-function FTO mutations in lean and obese individuals. Diabetes (2009) 1.54
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol (2011) 1.54
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care (2010) 1.50
Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care (2007) 1.50
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet (2011) 1.33
Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther (2010) 1.30
New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab (2007) 1.27
The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One (2013) 1.22
Obesity and persistent organic pollutants: possible obesogenic effect of organochlorine pesticides and polychlorinated biphenyls. Obesity (Silver Spring) (2010) 1.19
Evolution of analytical performance in portable glucose meters in the last decade. Diabetes Care (2003) 1.19
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol (2009) 1.19
Effect of long-term whole body vibration training on visceral adipose tissue: a preliminary report. Obes Facts (2010) 1.14
Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol (2005) 1.13
Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care (2011) 1.12
Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes (2011) 1.12
Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care (2012) 1.05
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord (2011) 1.04
Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status. Diabetes Metab Res Rev (2006) 0.99
Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. Arterioscler Thromb Vasc Biol (2013) 0.98
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One (2013) 0.97
Glucose control and use of continuous glucose monitoring in the intensive care unit: a critical review. Curr Diabetes Rev (2008) 0.97
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism (2009) 0.97
Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. J Clin Invest (2013) 0.96
ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems. Diabetes Technol Ther (2013) 0.96
High glycemic variability assessed by continuous glucose monitoring after surgical treatment of obesity by gastric bypass. Diabetes Technol Ther (2011) 0.95
Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res (2007) 0.95
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia (2013) 0.95
Sleep-disordered breathing and uric acid in overweight and obese children and adolescents. Chest (2007) 0.94
Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol (2012) 0.94
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin (2005) 0.91
The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine (2007) 0.91
Efficacy and safety of the weight-loss drug rimonabant. Lancet (2008) 0.91
Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS One (2012) 0.90
The effect of weight loss on sleep-disordered breathing in obese teenagers. Obesity (Silver Spring) (2009) 0.90
The effect of whole body vibration short-term exercises on respiratory gas exchange in overweight and obese women. Phys Sportsmed (2009) 0.89
Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Ther (2012) 0.89
A review of current evidence with continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol (2008) 0.89
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin (2008) 0.89
Association of the BDNF Val66Met variation with obesity in women. Mol Genet Metab (2008) 0.88
Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. Curr Diabetes Rev (2008) 0.88
Dynamics of organohalogenated contaminants in human serum from obese individuals during one year of weight loss treatment. Environ Sci Technol (2013) 0.87
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens (2008) 0.87
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept (2012) 0.87
Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study. Diabetes Technol Ther (2011) 0.86
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2015) 0.86
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine (2012) 0.86
Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res (2004) 0.86
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol (2013) 0.86
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. Diabetes Ther (2013) 0.86
Sleep-disordered breathing and C-reactive protein in obese children and adolescents. Sleep Breath (2013) 0.85
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary (2015) 0.85
A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. Diabetes Technol Ther (2011) 0.83
Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol (2010) 0.83
Overweight in adolescents: differences per type of education. Does one size fit all? J Nutr Educ Behav (2008) 0.83
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther (2012) 0.83
Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device. Diabetes Metab Res Rev (2004) 0.83
Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals. Metabolism (2013) 0.83
Metformin and insulin in type 1 diabetes: the first step. Diabetes Care (2003) 0.82
Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. Value Health (2010) 0.82
Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs (2009) 0.81
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes (2013) 0.80
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) (2009) 0.80
Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. J Clin Psychopharmacol (2014) 0.80
Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. J Clin Endocrinol Metab (2002) 0.80
Possible role for ENPP1 polymorphism in obesity but not for INSIG2 and PLIN variants. Endocrine (2009) 0.80
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin (2011) 0.79
Pragmatic diabetes management in nursing homes: individual care plan. J Am Med Dir Assoc (2013) 0.79
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health Qual Life Outcomes (2013) 0.78
Coenzyme Q as an antiadipogenic factor. Antioxid Redox Signal (2010) 0.78